A groundbreaking discovery about Mounjaro: It can reverse deadly liver disease. Belinda and Gillian, once facing the grim prospect of liver failure, are now on the path to recovery, thanks to this remarkable treatment. Doctors are praising its effectiveness.
Belinda Whitlock, a 55-year-old mother of four, initially attributed her fatigue, nausea, and stomach pain to menopause. Despite hormone replacement therapy, her health worsened. An ultrasound scan, intended for vaginal bleeding, unexpectedly revealed signs of a fatty liver, leading to a diagnosis of advanced liver fibrosis. This condition, linked to obesity and long-term inflammation, had already taken a toll on her family, as her mother died of liver cancer at 46.
Belinda's lifestyle changes, including a Mediterranean diet, coffee, and no takeaways, yielded results. However, her liver scans showed little improvement. Seeking a new approach, she turned to GLP-1 weight-loss drugs, paying hundreds of pounds monthly for a private prescription. The results were astonishing: she lost five stone and her liver fibrosis reversed.
Experts highlight the alarming rise in liver disease, largely due to poor diets and sedentary lifestyles. The condition progresses through four stages, starting with excess fat, which can lead to scarring and cirrhosis if untreated. The British Liver Trust estimates 80% of those with fatty liver disease are undiagnosed, as early stages often show no symptoms. Cirrhosis, a severe form, is irreversible without a transplant.
Professor Philip Newsome, a liver expert, emphasizes the promise of weight-loss drugs in treating liver disease. Compelling research evidence suggests they can reverse liver damage, a significant advancement. Doctors attribute the surge in cases to poor diets and inactivity, emphasizing the importance of early diagnosis and treatment.
Gillian Scott, a 57-year-old civil servant, was diagnosed with cirrhosis due to uncontrolled type 2 diabetes and obesity. After switching to Mounjaro, she lost nine stone and her condition improved from cirrhosis to fibrosis. This success story, supported by a 2024 study in the New England Journal Of Medicine, shows 62% of patients on the highest dose of Mounjaro saw their fatty liver disease resolve.
However, GLP-1 drugs are not yet approved on the NHS for this condition, causing financial strain for patients like Belinda, who is paying hundreds of pounds monthly for her treatment. The delay in approval highlights the need for the NHS to recognize the benefits of these drugs in saving lives.
